ORIGINAL RESEARCH article
Front. Med.
Sec. Hematology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1673206
This article is part of the Research TopicNew frontiers in safeguarding blood component transfusions: Innovative approaches to bacterial risk reductionView all articles
Perioperative Management of severe Factor VII Deficiency: A single center experience in China
Provisionally accepted
- The Affiliated Hospital of Qingdao University, Qingdao, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Inherited factor VII (FVII) deficiency is a rare autosomal recessive disorder which clinical phenotypes are highly variable. Many studies observed the absence of a clear-cut and consistent correlation between bleeding symptoms and FVII levels. Perioperative bleeding is a major concern in patients with FVII deficiency but validated recommendations about the perioperative management of replacement therapy (RT) with FVII are lacking. Our study retrospectively summarized and analyzed perioperative hemostasis management of severe FVII deficiency in 20 patients. We found that replacement therapy is generally effective, and there is no significant correlation between the perioperative hemorrhagic complications after RT and the severity of FVII level before RT. And through multivariate statistical analysis and the retrospective analysis of other coagulation factors deficiency in our center, we found that postoperative secondary hyperfibrinolysis in patients with FVII deficiency may not be universal. It may be necessary to give the treatment of antifibrinolytics for patients undergoing surgeries in high fibrinolytic sites during the perioperative period. Besides, clinical data such as bleeding phenotype, the bleeding history and surgical sites should attract appropriate attention to perioperative treatment and monitoring.
Keywords: Factor VII Deficiency, Perioperative management, Replacement therapy, Prothrombin complex, Antifibrinolytic Agents
Received: 25 Jul 2025; Accepted: 01 Sep 2025.
Copyright: © 2025 Zhu, Zhao, Xu, Lu and Jialiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Guan Jialiang, The Affiliated Hospital of Qingdao University, Qingdao, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.